Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/Beta-catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.